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Abstract
Purpose: To report clinical features, pathology characteristics, and treatment outcomes of five patients with Rosai‑Dorfman disease (RDD).
Methods: A retrospective case series of patients with RDD from the Ocular Oncology Service of Wills Eye Hospital between 1974 and 2018.
Results: There were six eyes of five patients (3 males, 2 females) with ophthalmic manifestations of RDD. The mean age at the initial presentation
was 33 years (median 35, range 10–52 years). Before referral, the tumor was initially suspected to be lymphoma (n = 3), idiopathic orbital
inflammation (n = 2), or pterygium (n = 1). The disease was unilateral (n = 4) or bilateral (n = 1). The mean duration of symptoms was 9
months (median 8, range 5–24 months). The disease produced nodules in the conjunctiva (n = 4) or orbit (n = 2). Two patients with conjunctival
involvement had corneal involvement. One patient with bilateral conjunctiva lesions demonstrated bilateral orbital involvement and bilateral
anterior uveitis. The mean tumor basal dimension was 13 mm (median 9, range 6–27 mm) for conjunctiva lesions and 37 mm (median 37,
range 34–40 mm) for orbital lesions. The main symptom (per patient) included proptosis (n = 2), palpable mass (n = 1), and foreign body
sensation (n = 2). No patient experienced pain or tenderness. Palpable, nontender lymphadenopathy was detectable in two patients in the
cervical and inguinal lymph nodes. Systemic involvement with paranasal sinusitis and mediastinal/pulmonary lymphadenopathy occurred in
two patients, both with orbital involvement. Surgical resection was performed for all patients. At a mean follow‑up of 31 months (median 12,
range, 10–76 months) after the surgery, tumor control was achieved in all six eyes without local recurrence.
Conclusion: In this series of six eyes with RDD, patients with orbital and/or intraocular disease were more likely to demonstrate lymphadenopathy
and systemic involvement, while those with unilateral perilimbal conjunctival tumors remained localized.
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Introduction
Rosai‑Dorfman disease (RDD) is a rare, non-malignant,
histiocytic disorder that was first described in 1969 by
Rosai and Dorfman as a new clinicopathological entity,
often presenting with painless cervical lymphadenopathy.1
This pseudo‑lymphomatous disorder, also known as
“sinus histiocytosis with massive lymphadenopathy,” has
characteristic histopathologic features of abundant histiocytes,
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often demonstrating emperipolesis, representing engulfed
lymphocytes and lymphoid cells.1
The disease has unclear etiology and usually demonstrates a
self‑limited but prolonged course.1,2 RDD has been reported
worldwide, generally in children and young adults, and less
commonly in older adults.2,3 According to the American
Histiocyte Society, RDD is classified as a histiocytic disorder
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characterized by the accumulation of macrophage, dendritic, or
monocyte‑derived cells in various tissues and organs. Unlike
Langerhans cell histiocytosis and Erdheim‑Chester disease,
RDD does not display BRAF mutation (BRAF V600E) and
is typically negative for CD1 marker.4

age at presentation was 33 years (median 35 years, range
10–52 years). The mean duration of symptoms before treatment
was 9 months (median 9 months, range 5–24 months). Patient
demographics are listed in Table 1. The case reports are given
below separately.

RDD usually manifests inside lymph nodes in the area of the
head and neck, but 43% of patients present with extranodal
involvement, mostly in skin, upper respiratory tract, bone,
periocular, and ocular tissue.2 Less than 10% of RDD cases
have ocular findings,2,3 and those in the periocular region
usually manifest as an orbital mass.3‑9 Other ophthalmic
manifestations include epibulbar mass, scleritis, corneal lesion,
uveitis, choroidal mass, serous retinal detachment, and lacrimal
duct obstruction.3‑13 Herein, we describe a series of six eyes in
five patients with biopsy‑proven RDD and review the clinical
and pathologic features.

Case #1

Methods
RDD was diagnosed in six eyes of five patients evaluated on the
Ocular Oncology Service at Wills Eye Hospital, Philadelphia,
PA, USA, between January 1974 and July 2018. Patient data
were retrospectively reviewed. Institutional review board
approval was obtained from Wills Eye Hospital, and this study
adhered to the tenets of the Declaration of Helsinki. Informed
consent was obtained from the patients, patient’s parent, or
guardian. The diagnosis of RDD was based on clinical and
histopathologic examination in all patients.

A 22‑year‑old White female noted a nodule on the right eye.
Despite treatment with topical prednisone, the mass persisted.
On referral, visual acuity was 20/30 in the affected right eye.
There was a non-pigmented, vascular conjunctival mass
measuring 6 mm in diameter and 2 mm in thickness, located
superiorly at the limbus with limited corneal stromal invasion
for 2 mm. There was no lymphadenopathy. Excisional biopsy
revealed inflammatory infiltration with lymphocytes, plasma
cells, and histiocytic cells and demonstrating positive staining
for CD68, CD163, and S‑100 protein, and negative staining for
CD1a. Rare emperipolesis was noted in the small specimen. On
examination 12 months after surgery, the corneal infiltration
improved, and visual acuity was 20/25 [Figure 1a and b].

Case #2

A 35‑year‑old White male presented with left eye irritation,
redness, and conjunctival mass for 1 month that did not
respond to topical corticosteroids. On referral, visual acuity
was 20/25, and the left eye revealed a non-pigmented, vascular
conjunctival mass measuring 6 mm in diameter and 2 mm in
thickness, located inferiorly at the limbus with 4 mm of corneal
stromal invasion, leading to stromal lipid deposition. There

An ophthalmology examination and systemic history were
taken at the initial consultation. Data from medical records
were extracted, including patient age at diagnosis (years),
race (White, African American, Hispanic, or Asian),
sex (males or females), ocular symptoms, cutaneous or other
extraocular lesions, and prior ocular treatment. The complete
ophthalmological examination included Snellen visual
acuity measurement, intraocular pressure, anterior segment
examination by slit‑lamp biomicroscopy, and posterior
segment examination by indirect ophthalmoscopy at each
visit. Baseline tumor features such as location, laterality,
number of tumors, and tumor size (largest basal diameter and
thickness in millimeters) were recorded. For patients with
orbital involvement, imaging of the tumor was performed
with magnetic resonance imaging (MRI) or computed
tomography (CT).
Treatment modalities included incisional or excisional biopsy,
adjunctive corticosteroids (topical, periocular, and oral),
and/or chemotherapy. Tumor response (regression, stable,
or progression) and tumor recurrence after treatment were
recorded.

Results
Five patients with ocular RDD were identified over this
43‑year period. There were three males and two females, with
unilateral (n = 4) or bilateral (n = 1) involvement. Mean patient
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Figure 1: (a) Slit‑lamp photograph of right eye in 22‑year‑old woman
(case #1) showing pink elevated limbal nodule with cornea stromal
keratitis. (b) Twelve months after surgery, there was no evidence
of recurrence. (c) Elevated, pink, conjunctival lesion of the left eye
in 35‑year‑old man (case #2) with corneal stromal lipid infiltration.
(d) Slit‑lamp photograph of same eye after resection showing minor
corneal opacity. (e) Bilateral asymmetric conjunctival tumors in
45‑year‑old man (case #3). (f) Following resection and sub‑tenon
triamcinolone, the tumor remained under control at 4 years
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A 45‑year‑old African‑American male presented with a
painless elevated forniceal nodule on both eyes for 2 years,
with no response to topical corticosteroids. On referral, visual
acuity was 20/25 in both eyes. Each eye demonstrated a nonpigmented, vascular conjunctival mass in the inferotemporal
fornix, extending into the orbit and measuring 6 mm in
diameter and 4 mm in thickness. There was no corneal
invasion. There was bilateral lymphadenopathy of the neck
and groin. Ten months before presentation, a biopsy of the left
groin mass revealed RDD. Excisional biopsy of the tumors
on each eye revealed RDD with obvious emperipolesis and
histiocytic cells with positive reactivity for CD68, CD163,
and S‑100 protein, and negative for CD1a. One year after the
presentation, the patient developed severe nasal congestion and
dyspnea with voice alterations. Chest and neck CT revealed
a 4 cm nasal mass, 3.5 cm mediastinal mass with tracheal
compression, and 8 cm mass encasing the aortic arch, believed
to represent systemic RDD. Intravenous rituximab (6 cycles)
and chemotherapy with cyclophosphamide, doxorubicin,
vincristine, and prednisone were delivered, with tumor control.
Two years after the initial presentation, the conjunctival/orbital
tumors were controlled, but uveitis developed in both eyes with
anterior chamber keratic precipitates and inflammatory cells.
This was treated with sub‑Tenon’s triamcinolone and topical
prednisone in both eyes. At 4 years following initial surgery,
visual acuity was 20/25 in both eyes, and there was no further
recurrence of active uveitis [Figure 1e and f].
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was no lymphadenopathy. Excisional biopsy revealed mixed
inflammatory cells, rich in histiocytes, positive for CD68,
CD163, and S‑100 protein, and negative for CD1a. Classic
emperipolesis was not detected in the small specimen, but
other findings were consistent with RDD. Ten months after
surgery, the visual acuity was 20/20, and the corneal stromal
lipid deposits had decreased substantially [Figure 1c and d].

Case #3

Age/race/sex
Case

Table 1: Summary of five cases of Rosai-Dorfman disease with ophthalmic involvement

Systemic
involvement

Treatment
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A 10‑year‑old White male developed 9 months of painless right
eyelid swelling that failed systemic corticosteroids. On referral,
visual acuity was 20/30 in the right eye, and the globe was
intact without inflammation. There was 4 mm right proptosis
from a firm, fixed, and nontender lacrimal gland mass, depicted
on MRI with enhancement [Figure 2a and b]. Laboratory
studies revealed normal complete blood count (CBC), normal
erythrocyte sedimentation rate, and negative testing for Lyme,
Bartonella, and Tuberculosis. Excisional biopsy revealed
a firm encapsulated mass with histopathologic evaluation
demonstrating diffuse mixed inflammatory infiltration with
variable fibrosis and emperipolesis. Occasional multinucleated
giant cells were positive for CD68 and S‑100, and negative
for CD1a. At 6 years after surgery, the visual acuity remained
20/20 with no further local recurrence or systemic disease.

Case #5

A 52‑year‑old White female noted 10 months history of a
lump on her right upper eyelid and multiple lumps in her neck
Journal of Current Ophthalmology | Volume 32 | Issue 3 | July-September 2020
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Figure 2: Orbital presentation of Rosai‑Dorfman disease. (a) External
photograph of 10‑year‑old male (case #4) with right upper eyelid mass,
showing blepharoptosis and inferolateral globe displacement. (b) Axial
T1 magnetic resonance imaging showing large, well‑defined mass
in the lacrimal gland region of the orbit. (c) External photograph of
52‑year‑old woman (case #5), showing erythematous right upper eyelid
mass, blepharoptosis, and mild proptosis. (d) Coronal orbital computed
tomography scan showing a large homogeneous lesion in lacrimal gland
region of the orbit. White arrow shows involvement in para nasal sinuses

and submandibular region, shown on fine‑needle aspiration
biopsy to have atypical mature lymphocytes. She also noted
nasal congestion and epistaxis for 4 months. On referral,
visual acuity was 20/40 in the affected right eye, and the
globe was intact. There was a large mass fixed to orbital rim
superotemporally that demonstrated marked enlargement of the
right lacrimal gland and opacification of the fronto‑ethmoidal
sinuses [Figure 2c and d]. Laboratory examination showed
normal CBC. Following surgical excision, histopathology
revealed large histiocytes with copious eosinophilic cytoplasm,
positive for CD68, CD163, and S‑100 protein [Figure 3], and
negative for CD1a, consistent with RDD. The histiocytes
showed prominent emperipolesis. Subsequent sinus mucosal
biopsy revealed features of RDD. Ten months after surgery, the
visual acuity was 20/30, and there was no recurrence.

Discussion
It is estimated that there are fewer than 100 cases of RDD in
the United States each year.13 The first reports of RDD were
mostly in the African‑American population, and subsequent
studies revealed that this disease has no specific predilection
for geographic location or race.2 This tumor is usually benign,
asymptomatic, and it takes years to develop.9 The clinical
course of RDD is chronic and unpredictable with episodes of
exacerbation alternating with periods of remission.2 Foucar
et al. reported progressive disease in only 1%, spontaneous
regression in 21%, and stable disease in 78% of patients.2
The precise etiology of RDD remains unknown; however,
certain etiologic factors have been suspected including
bacterial (Klebsiella), virus (parvovirus B 19 or Epstein‑Barr
virus), or an aberrant response to an unspecified antigen
such as human herpes virus 6.14‑16 The increased incidence
of serum autoreactive antibodies during active disease,

Figure 3: (a) Photomicrographs of the orbital mass show plump
histiocytes surrounded by mature lymphocytes and plasma cells
(H and E, ×40). (b) Higher magnification shows engulfed lymphocytes
(emperipolesis, arrow) that can be found within the cytoplasm of some
of the enlarged histiocytes (H and E, ×100). (c) CD163 cytoplasmic
positivity in histiocytes with negative stain for lymphocytes and plasma
cells (d) immunohistochemical staining of histiocytes is strongly
positive for S‑100 protein (Photograph courtesy of Dr. Tatyana Milman,
Department of Ophthalmic Pathology, Wills Eye Hospital, Philadelphia,
PA, USA)

presence of characteristic histiocytes derived from circulating
mononuclear cells, and a long history of disease suggest a
possible pathogenic correlation with an immune dysregulatory
process.14
The differential diagnosis of RDD includes Langerhans cell
histiocytosis, lymphoma, and inflammatory pseudotumor.
The diagnosis of RDD depends on histopathologic and
immunohistochemical testing.2 Classically, there is a population
of histiocytes with prominent vesicular nucleoli and abundant
pale cytoplasm that often manifest entire imbibed lymphocytes,
plasma cells, and neutrophils, termed “emperipolesis.”2
Furthermore, RDD tissue shows immunoreactivity for CD163
[Figure 3c], CD68 and S-100 [Figure 3d] but negative for
CD1a, a feature of Langerhans cell histiocytosis. Nuclear
atypia and mitotic figures are rare [Figure 3a and b].2,17
Foucar et al.2 reviewed a large series of RDD in 423 patients
and noted extranodal manifestations of this disease to
involve the skin, upper respiratory tract, and bone. They also
documented 36 (8.5%) cases with periocular involvement
including orbit (n = 26), eyelid (n = 5), uvea (n = 4),
and conjunctiva (n = 1).2 Others have shown that orbital
involvement is the most common site for the ophthalmic
manifestation of RDD.3‑9 Orbital RDD typically involves
the soft tissue of intraconal space, as opposed to other
xanthogranulomatous disorders, which tend to be extraconal
or involve anterior orbital spaces.9 In a report, between
34 cases of RDD, 24 had an orbital mass, 6 of which were
confined to the lacrimal gland.9 While the majority of patients
with orbital involvement have concurrent lymphadenopathy,
some may present with an orbit as the sole extranodal site
without the synchronous nodal disease.3 A minority of these
patients may include other extranodal sites such as skin or
paranasal sinuses at the same time.3 In our series of five
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patients, three had orbital involvement (cases 3, 4, and 5),
and of those, two (cases 3 and 5) had synchronous regional
lymphadenopathy with concurrent paranasal sinusitis.
Tran et al.18 reviewed 20 cases of RDD reported with an
epibulbar mass. They described the mass as pink, red, or
salmon‑color and fleshy appearance. Unilateral involvement
was seen in 70% (n = 14) and concurrent lymphadenopathy
in 15% (n = 3). 18 These lesions typically arose at the
limbus and occasionally extended onto the cornea causing
inflammatory keratitis. A lack of endothelial or anterior
chamber inflammation was documented.19 Fernandes et al.
reviewed 9 cases of RDD with limbal involvement, and
only 2 demonstrated lymphadenopathy.20 In our series, there
were 3 cases of conjunctival involvement, 2 with unilateral
perilimbal tumor (cases 1 and 2) and no nodal involvement,
and 1 with bilateral forniceal tumors with orbital invasion
(case 3) and systemic involvement.
The involvement of RDD within the eye is exquisitely
rare. Choi et al. evaluated four patients with intraocular
involvement (retinal detachment, ciliary body mass, scleritis,
and anterior uveitis) and noted that they all demonstrated
multi‑organ disease, including lymph nodes, sinusitis, renal, and
lung involvement.4 In our series, there was one patient (case 3)
with bilateral anterior uveitis, and he additionally demonstrated
chronic sinusitis and cervical, inguinal, and mediastinal
lymphadenopathy from RDD. Based on these findings, we
believe that patients with intraocular and/or bilateral RDD are
at risk for systemic involvement as compared to those with
limbal tumor who are very low to no risk.
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